Santarus Inc (SNTS)

[biginvestors]

Santarus, Inc. and Pharming Group NV announced that they have reached agreement with the U.S. Food and Drug Administration (FDA) on the design of a Phase III clinical study with the investigational drug RHUCIN (recombinant human C1 inhibitor) under the Special Protocol Assessment (SPA) process that is intended to support the submission of a Biologics License Application (BLA). RHUCIN is being evaluated for the treatment of acute attacks of angioedema.